cyrilzakka/clinical-trials huggingface dataset:
A Randomized Controlled Trial of an Antenatal Intervention to Increase Exclusive Breastfeeding

The investigators will conduct an educational intervention for pregnant women who are planning to breastfeed to promote exclusive breastfeeding and to increase the duration of breastfeeding.

The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding.

Eligibility Criteria:
Inclusion Criteria:

1. singleton pregnancy,
2. primiparous
3. 18 years of age or older,
4. at least 36 weeks of gestation,
5. Cantonese speaking,
6. Hong Kong resident,
7. no serious medical or obstetrical complications,
8. staying in Hong Kong for at least 6 months after delivery, and
9. intention to breastfeed.

Exclusion Criteria:

Participants will be excluded from the study if they are not entitled to health benefits in Hong Kong (NEP).
Solyx Single-Incision SlingDynamic Intraoperative Standing Sling Technique (DISST) as an Office-based Procedure

This study will assess the feasibility and success of performing the SolyxTM SIMUS in the office using the Dynamic Interactive Standing Sling Technique (DISSTTM). Study endpoints will be feasibility, composite success, complications, and patient and physician acceptance.

The single-incision midurethral sling (SIMUS) is a procedure where there are no exit incisions. There is a 15 mm suburethral incision with the sling being attached with anchors to the obturator muscle on each side. This procedure has potentially lesser side-effects compared to the longer slings however, the literature has not found the SIMUS to be as effective as the long slings. In our recently published study, the DISSTTM technique has significantly improved the success of the SIMUS procedure as the sling can be tested for proper application in vivo.

As we have performed several of these procedures in the operating room entirely under local anesthesia, we have decided to perform this procedure in an office setting using the same safety precautions as in a hospital operating room.

Performing this procedure in the office has significant benefits for the patient, the healthcare industry, and the economy overall. Moving away from a hospital setting has significant psychological benefits. This will increase patient acceptance and therefore will become appealing to many more women who may be shying away from treatment.

It would also eliminate the risk of nosocomial infections for the patient and family members, improve efficiency as the wait time would be negligible, and would reduce the expense of the entire treatment as hospital costs would not feature in the equation.

This study will assess the feasibility and success of performing the SolyxTM SIMUS in the office using the Dynamic Interactive Standing Sling Technique (DISSTTM). Study endpoints will be feasibility, composite success, complications, and patient and physician acceptance.

Eligibility Criteria:
Inclusion Criteria:

* SUI with hypermobility of the urethrovesical (UV) junction
* American Society of Anesthesiologists (ASA) classes I or II
* Ages ranging 21-89 years
* Have the ability to stand for CST during the procedure
* Have failed behavioral therapy
* Completed childbearing

Exclusion Criteria:

* ASA classes III or IV
* Need for concomitant surgery
* Poor compliance for office-based approach
* Demonstrate concomitant urgency incontinence on urodynamic testing
The Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value-Based Payment System

This trial will prospectively evaluate the impact of integrating AI-ECG within the pay-for-performance program on improving the diagnosis, treatment, and clinical outcomes of occlusion myocardial infarction patients by promoting accurate and timely diagnoses through financial incentives.

The investigators have developed an AI-ECG system that provides real-time notifications for patients with potential occlusion myocardial infarction. This AI algorithm is seamlessly integrated into the Hospital Information System, allowing for the automatic generation of reports whenever an ECG is performed. The purpose of this study is to evaluate the impact of AI-ECG on the timely diagnosis of STEMI, including patients' outcomes and healthcare costs.

Eligibility Criteria:
Inclusion Criteria:

* Patients in the emergency department
* Patients received at least 1 ECG examination.

Exclusion Criteria:

* The patients received ECG at the period of inactive AI-ECG system.
* Patients with a history of coronary angiography within the past 3 days.
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study

This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls

Dolutegravir (DTG) based dual antiretroviral therapy constitutes a paradigm shift from triple drug based therapy. Data outside clinical trials are scarce. This study evaluates the value of DTG/3TC in real life.

Eligibility Criteria:
Inclusion Criteria:

Plasma HIVRNA \<50c/mL on triple drug cART regimen including 2NRTI In care in a HIV treatment center in the Netherlands Consented to ATHENA participation

Exclusion Criteria:

Documented mutations associated with 3TC or DTG resistance of at least low level Documented inadherence by the treating physician or HepB coinfection (cases only)
Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility

The aim of this study is to evaluate gastroesophageal reflux disease - health related quality of life (GERD-HRQL) after electrical stimulation of the lower esophageal sphincter (LES) in patients with gastroesophageal reflux disease (GERD) and esophageal dysmotility.

Background The growing burden of gastroesophageal reflux disease (GERD) still impacts healthcare costs intensively. Although the treatment with proton pump inhibitor (PPI) is effective in many cases, surgical treatment remains relevant due to a large amount of PPI refractory GERD. Laparoscopic fundoplication (LF) is considered as standard procedure, but this type of surgery is linked to side effects as dysphagia, gas bloating and inability to belch. Especially patients with ineffective esophageal motility (IEM) are prone to postoperative dysphagia after LF. Lower esophageal sphincter electrical stimulation (LES-EST) was introduced as an alternative technique to avoid side effects of LF. Rodriquez et al. have bee demonstrated that LES-EST significantly raises the LES pressure and improved GERD symptoms such as heartburn and regurgitation. The advantage of this procedure is that the anatomy of the esophageal-gastric junction is not altered dramatically. Notably, patients with severely disordered esophageal peristalsis will benefit from this low-risk profile.

After successful implementation of this technique at the Medical University of Vienna (EK 1149/2014), a prospective evaluation of data with the well established gastroesophageal reflux disease - health-related quality of life is next. Patients with esophageal motility disorder, who undergo LES-EST, will be investigated towards side effects such as gas-bloating, inability to belch, flatulence and dysphagia.

Eligibility Criteria:
Inclusion Criteria:

* Subject is indicated for LES Stimulation and plans to undergo antireflux surgery.
* Subject is meeting the criteria of IEM (Chicago classification v3.0)
* Subject provides signed informed consent

Exclusion Criteria:

* Subject is within a vulnerable population or is unable to understand the informed consent.
* Subject is unwilling to attend follow-up visits.
French Wilson Disease Registry

This registry concerns adults and children with Wilson's disease. The collection of a large amount of data will allow a better understanding of the epidemiology of this rare disease, in particular the age of onset according to the hepatic or hepato-neurological forms, but also the geographical distribution of patients consulting in France. This database will also make it possible to know all the therapies prescribed to "Wilsonian" patients. The genetic study of these patients will make it possible to specify the various genetic mutations involved in Wilson's disease. The information (clinical, biological, radiological and genetic) relating to the disease will be entered by a doctor or a professional specialising in Wilson's disease.


Eligibility Criteria:
Inclusion Criteria:

* All patients suffering from Wilson disease

Exclusion Criteria:

* Lack of written consent from the patient or their legal representative
Can Additional Drug Therapy Accelerate Response Time to Antidepressants

Antidepressants are commonly prescribed and are effective for treating depression. However, they generally take 4-6 weeks for a therapeutic response. This study is evaluating whether simultaneous treatment with thyroid hormone or pindolol can decrease the response time ("getting better faster") in patients who are starting SSRI treatment.

Major depression is an illness with substantial personal and economic morbidity (Greenberg et al.1993) and antidepressants are the cornerstone of treatment. As antidepressants usually require 3-6 weeks of use before a response occurs, an effective antidepressant acceleration strategy would reduce the time of onset for an effective antidepressant response. This has significant clinical implications, as it could lead to reduced symptom morbidity, potentially reduce health care cost (i.e. shorter hospital length of stay), and improve functional capacity and quality of life.

The goal of this study is to enhance our understanding of strategies that accelerate or produce a more rapid treatment response in depression. This could lead to reduced symptom morbidity, potentially reduce health care cost (i.e. shorter hospital length of stay), and improve functional capacity and quality of life.

The study goals are: 1.) To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can accelerate the treatment response (i.e. faster rate of improvement), 2.) To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can augment or enhance treatment response (i.e. greater reduction in depressive symptoms at end of study phase), adn 3.) To assess whether gender influences the acceleration of augmentation response rate of liothyronine or pindolol.

Eligibility Criteria:
Inclusion Criteria:

1. Patients, male and female, between the ages of 18 to 65
2. DSM-IV criteria for major depressive disorder
3. No prior SSRI medication treatment (if a patient has discontinued a non-SSRI medication for side effects, they will not be excluded)
4. Ability to be followed clinically for 6 weeks
5. Each patient must understand the nature of the study and must sign an informed consent form

Exclusion Criteria:

1. Severe suicidality (as defined by Beck Depression Inventory Question 9, responses 2 or 3)
2. Major Axis I mental illness other than major depressive disorder
3. Unstable medical health specifically cardiovascular disease, abnormal EKG, history of severe drug allergy, poorly controlled diabetes, and asthma (pindolol contraindication)
4. History of thyroid disease or abnormal TFT's (stage I or II)
5. Need for adjunctive antipsychotic use or additional benzodiazepine during the study
6. Pregnancy
7. Seizure disorder
8. A positive urine toxicology screen
Nitazoxanide for Treatment of Cryptosporidium in Children

The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months. The main questions it aims to answer are:

* Does NTZ treatment of diarrheal Cryptosporidium infection lower the number of days of diarrhea?
* Does NTZ treatment of diarrheal and non-diarrheal Cryptosporidium infection lower the number of days that parasites can be found in the stool?

Researchers will compare NTZ to a placebo (a look-alike substance that contains no drug) to see if NTZ works to treat Cryptosporidium.

Participants will:

* Take NTZ or placebo for 3 days
* Receive regular visits from field research assistants
* Provide blood and urine samples


Eligibility Criteria:
Inclusion Criteria:

* tests positive for Cryptosporidium by stool point-of-care test, with or without active diarrhea
* family plans on remaining in the area for next 6 months

Exclusion Criteria:

* history of hypersensitivity to nitazoxanide.
* taking warfarin. Tizoxanide, the metabolite of nitazoxanide is highly bound to plasma proteins and may compete with binding sites of other highly plasma bound drugs with narrow therapeutic indices, including warfarin.
* history of renal insufficiency or a baseline serum creatinine = 40 µmol/L. Renal clearance of the drug has not been studied.
* history of hepatic dysfunction or serum aspartate aminotransferase (AST) ;
* 50 U/L, serum alanine transaminase (ATL) ;
* 50 U/L, or serum bilirubin ;
* 23 µmol/L. Hepatic clearance of the drug has not been studied.
Wound Fluid Protease Levels During Use of Novel Wound Dressing

This study is being conducted to characterize the way leg wounds respond to a new type of wound dressing, compared to wounds in patients who are not using the new dressing. The investigators will collect wound fluid for biochemical analysis, and they will measure the wound healing that occurs with and without the new dressing.

Abnormal wound healing is characterized by prolonged inflammation and excess degradation of the extracellular matrix through the activity of proteinases and other enzymes. Wound fluids can provide biochemical information about the healing status of chronic wounds and the effects of wound treatments. In this study the investigators will obtain samples of wound fluid and measure healing in wounds randomized to receive the novel dressing or a control. The findings will be compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of venous insufficiency
* One or more partial or full-thickness venous leg ulcers 5-24 sq. cm in size without evidence of clinical infection
* Ankle/brachial index 0.8 and above
* Duration of wound up to one year
* Able to return to wound clinic for weekly evaluations
* Has signed Institutional Review Board approved informed consent

Exclusion Criteria:

* Exposed bone or tendon or necrotic wound base
* Signs or symptoms of cellulitis or osteomyelitis at the target ulcer
* Allergy to a component of the novel dressing or compression wrap
* Third degree burn
* Vasculitis, severe rheumatoid arthritis or other collagen vascular disease
* Receiving antibiotics
* Pregnant or lactating
Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia

This study is for patients with Severe Aplastic Anemia (SAA). A stem cell transplant from a genetically matched sibling donor can help or cure this disease in 85 to 100 percent of patients. Stem cells are immature blood cells that grow to become red blood cells, white blood cells or platelets. A genetic "match" means a brother or sister has same immune type (HLA type) as the patient. Unfortunately, few patients have a matched sibling donor. The chance of negative outcomes is much higher with other types of donors.

This study will test the success of a new approach to stem cell transplant for SAA. Patients in this study will receive drugs and radiation treatment to destroy their diseased bone marrow and to prepare them for stem cell transplant. Bone marrow is the tissue inside the bones where stem cells are made.Stem cells will be harvested from the blood or bone marrow of genetically matched unrelated donors or partially matched family donors. The stem cells will be filtered using a new device that is currently under study. The patients will receive large doses of the filtered stem cells (stem cell graft). Researchers want to find out how the study treatment affects patients, the disease, and the chances for survival.


Eligibility Criteria:
Inclusion Criteria:

* Age \< 21 years
* Diagnosis of severe aplastic anemia. (As defined by at least 2 of the following: ANC \< 500/μl, platelet count \< 20,000/μl, and a reticulocyte count \< 1% after correction for the hematocrit. In addition, the diagnostic bone marrow biopsy must contain less than 25% of the normal cellularity).
* Patient must have failed one or more courses of immunosuppressive therapy that included ATG. As immunosuppression may take up to 6 months to demonstrate a response, patients must have been observed to have failed immunosuppression for a minimum of six months.
* Absence of suitable HLA-matched sibling donor.
* Negative serum pregnancy test for females with child bearing potential.
* Patient/parent/guardian is able to provide informed consent.

Exclusion Criteria:

* Patients with a life expectancy \< 6 weeks.
* Patients with severe renal disease (creatinine clearance \< 40cc/min/1.73m2)
* Patients with pre-existing severe restrictive pulmonary disease (FVC \<40% of predicted)
ABCB1 SNPs as Predictors of PIPN

The study aim is to determine the allele frequencies of 1236 G\>A and 3435 G\>A in ABCB1 and study their association with the incidence and severity of paclitaxel-induced peripheral neuropathy while adjusting for other baseline covariates in Egyptian patients. Additionally, the study aimed at fitting and validating logistic regression models with the aforementioned SNPs evaluated in additive, dominant, overdominant, and recessive genetic models and performing diagnostics for the best model in terms of internal validity.


Eligibility Criteria:
Inclusion Criteria:

1. Egyptian females ≥18 years of age.
2. Histologically confirmed Breast Cancer.
3. Receiving conventional neoadjuvant or adjuvant weekly paclitaxel.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
5. Adequate organ reserves ((serum creatinine ≤1.5x upper normal limit (UNL), total bilirubin ≤1.5x UNL, absolute neutrophil count ≥1.5 x 10\^9/L, platelet count ≥100 x 10\^9/L, AST and ALT ≤3.0x UNL, and alkaline phosphatase ≤3.0x UNL).
6. No major neurological disease or symptoms prior to the start of paclitaxel therapy.
7. neither subjective nor objective evidence of metastatic disease.

Exclusion Criteria:

1. Pregnancy.
2. Patients with recurrent or metastatic (local or distant) breast cancer.
3. Neuropathic at the time of recruitment.
4. History of neuropathy prior to recruitment.
5. Previously exposed to taxanes or any other microtubule Inhibitors, or regimens including platinates.
6. Patients currently receiving dose-dense biweekly taxane-containing regimens.
Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients

To evaluate the relationship between abnormal protein or metabolite expression levels in peripheral blood and postoperative delirium in elderly patients undergoing cardiac surgery.


Eligibility Criteria:
Inclusion Criteria:

1. patients between 55 and 80 years old,
2. American Society of Anesthesiologists (ASA) physical status of II-III and New York Heart Association grade of II-III.
3. The planned cardiac surgery.
4. Hospitalization duration not less than 5 days.
5. The anesthesia time will be no less than 2 hours.All patients had a normal ability to hear, read and cooperate with neuropsychological tests.

Exclusion Criteria:

1. The pre-operative Montreal Cognitive Assessment (MoCA) score was less than 25,
2. Patients with dementia, history of neurological or psychiatric disease, hospital with anxiety depression scale (HADS) over eight points,
3. Currently use sedatives or antidepressants, Patients with substance dependence on drugs or alcohol.
4. Patients with liver and kidney dysfunction, patients with a history of cardiac surgery.
5. Admitted to the ICU for more than two days within the month preceding the current surgery,
6. Unable to cooperate with researcher's investigations.
Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers

To evaluate discomfort of a new coating and catheter material compared to SpeediCath (SC)

Intermittent catheterization is the preferred method for emptying the bladder in patients with spinal cord injury and neurogenic bladder dysfunction.

Coloplast have developed a new intermittent catheters. In this investigation this new test catheter will be compared with SpeediCat by assessing discomfort and pain associated with catheterization of healthy men. The reason for choosing healthy men is that many catheter users do not have full feeling in their urethra and therefore can not assess the discomfort.

55 healthy men who are ≥ 18 years and have no signs of urinary tract infection and do not have abnormalities, disease or have had operational interventions in the urinary tract will be included. They are recruited through advertisements on the website www.forsoegsperson.dk.

Eligibility Criteria:
Inclusion Criteria:

* • ≥18 years

  * Male
  * Signed informed consent
  * Negative urine stix (erythrocytes, leucocytes and nitrite)

Exclusion Criteria:

* • Abnormalities, diseases or surgical procedures performed in the lower urinary tract
The Development of Diagnosis and Prognosis Predictive Model for Peripheral Nerve Disease

This is a retrospective observational cohort study (MRN-PND), aiming to explore the utility of contrast-enhanced MRN (ceMRN) compared to plain MRN in diagnosing peripheral nerve diseases and predicting the prognosis of patients with these conditions. Additionally, artificial intelligence (AI) methods are employed to enhance the diagnostic accuracy of MRN for peripheral nerve diseases and to precisely predict disease outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who underwent MRN scanning at Wuhan Union Hospital between January 2015 and January 2025;
2. Age \> 18 years;
3. Definitive clinical diagnosis (either healthy individuals or patients with a specific condition).

Exclusion criteria：

1. Poor quality of imaging;
2. Incomplete clinical data or loss to follow-up;
3. Unclear clinical diagnosis.
Effect of Different Modalities of Cryotherapy on Post-Operative Pain in Patients With Symptomatic Irreversible Pulpitis

Problem statement: The post-operative pain after endodontic treatment. aim of study: The study is aiming to compare postoperative pain after submucosal cold saline injection (submucosal cryotherapy) (SMC) versus intra-canal cryotherapy (ICC) in mandibular single rooted premolars with symptomatic irreversible pulpitis with symptomatic apical periodontitis (SAP). The material and methods: Subjects and methods: sixty patients will be randomly divided into three groups: the SMC group, the ICC group, and the control group. The patients' postoperative pain will be recorded at 12, 24, and 48 hours postoperatively by questioning them. Quantification of substance P will be done using an ELISA test from peri-radicular fluid swab.


Eligibility Criteria:
Inclusion Criteria:

* Older than age of 18 years
* Participants willing to commit for the entire period of the trial and Both genders
* agreed to sign the written consent after full explanation of the study
* Having a mandibular single rooted premolar tooth with vital pulp
* These patients were also suffering from symptoms of symptomatic irreversible pulpitis and apical periodontitis, intermittent or continuous sharp pain that lasts longer after removal of the stimulus. on the basis of the clinical symptoms of severe preoperative pain (visual analogue scale)

Exclusion Criteria:

* Vulnerable group; prisoners, pregnant females, mentally ill, etc...
* Teeth with open apices
* A previous root canal treatment
* Sinus tracts
* Presence of periodontal pockets \>3 mm in the affected tooth